What Changed
- HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining
- Mining revenue fell 3% as HeartSciences (HSCS) merger partner Fortitude's nine-month loss widened.
- Fortitude Announces 15 MW Aurora, Nebraska Facility Now Participating in Southwest Power Pool Markets
Price Move History
- Daily moves over 5%
- 74 252 sessions, November 14, 2025 to November 16, 2026
- Largest daily move
- +55.4% close of June 23, 2026
- 1-year change
- -32.2% closing prices, November 14, 2025 to November 16, 2026
- 1-month change
- -31.1% closing prices, October 16, 2026 to November 16, 2026
Company Description
HeartSciences Inc. (NASDAQ: HSCS) is a healthcare information technology (HIT) and medical technology company focused on advancing electrocardiography (ECG or EKG) through the integration of artificial intelligence (AI). According to the company’s public disclosures, HeartSciences applies AI-based technology to ECGs to expand and improve their clinical utility, with the objective of making ECG a more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.
HeartSciences is developing and commercializing a device-agnostic, cloud-native ECG management and reporting platform, alongside a low-cost ECG hardware platform. The company states that it has one of the largest libraries of AI‑ECG algorithms and intends to provide these algorithms through a cloud-based solution that can work with existing ECG devices, as well as through its own hardware. Its solutions are designed to integrate into existing clinical workflows and hospital electronic health record (EHR) systems, aiming to support earlier detection of heart disease and improved patient outcomes.
MyoVista Insights Platform
A core focus of HeartSciences is its MyoVista Insights™ platform, described as a cloud-native, next-generation ECG management system. Company materials state that MyoVista Insights is designed to modernize legacy ECG management systems, improve workflow efficiency, streamline data management, and enhance clinical interpretation capabilities. It is being developed as a vendor- and device-agnostic platform capable of working with a broad range of ECG devices and file formats.
MyoVista Insights is also described as an ECG reporting and management system that can generate per-test, software-as-a-service (SaaS) based revenues. The platform is designed to host AI‑ECG algorithms from HeartSciences and third parties through an AI‑ECG marketplace, enabling clinical institutions to access AI‑ECG capabilities using existing ECG hardware. Company disclosures note that the platform is intended to integrate into hospital EHR systems and existing clinical workflows, and that it can be implemented without requiring healthcare providers to purchase new ECG devices.
HeartSciences reports that MyoVista Insights has been launched with early adopter reference sites and that a commercial version (Version 1.1) has been released. The company describes Version 1.1 as a major update intended to enhance clinical interpretation, improve workflow efficiency, expand interoperability across ECG devices, and deliver a more intuitive and efficient platform for cardiac care.
MyoVista wavECG Device
In addition to its software platform, HeartSciences is developing the MyoVista® wavECG™ device. Company descriptions state that the MyoVista wavECG is a resting 12‑lead ECG device designed to provide conventional ECG information while also supporting on‑device AI‑enabled solutions. It is described as being capable of hosting AI‑ECG algorithms and providing diagnostic information related to cardiac dysfunction that has traditionally only been available through cardiac imaging, in the same test that provides conventional ECG data.
HeartSciences has disclosed that it has submitted the MyoVista wavECG device to the U.S. Food and Drug Administration (FDA) for 510(k) premarket clearance. The company has also indicated that it elected to separate the FDA submissions for the MyoVista wavECG device and a specific impaired cardiac relaxation AI‑ECG software algorithm, in light of updated guidelines from the American Society of Echocardiography (ASE) for assessing Left Ventricular Diastolic Dysfunction (LVDD).
AI‑ECG Algorithms and Intellectual Property
HeartSciences states that it has one of the largest libraries of AI‑ECG algorithms and that these algorithms are being developed for deployment via MyoVista Insights and the MyoVista wavECG device. The company has highlighted AI‑ECG algorithms focused on conditions such as aortic stenosis and reduced ejection fraction. Public announcements note that the FDA has granted Breakthrough Device designation for HeartSciences’ aortic stenosis ECG algorithm, which is designed to detect moderate‑to‑severe aortic stenosis using ECG data.
The company also reports that it holds an extensive patent portfolio related to AI‑ECG technology. HeartSciences has disclosed that it has been granted multiple U.S. and international patents, including a foundational U.S. patent covering the estimation of echocardiographic parameters indicative of heart function using an ECG. The company characterizes its patent portfolio as covering AI‑ECG algorithm technology and related methods.
Business Model and Market Focus
Based on the company’s statements, HeartSciences’ business model centers on applying AI to ECGs to enhance their diagnostic value and clinical utility. The company is building a device‑agnostic, cloud‑based ECG management and AI‑ECG platform that can be used with existing ECG devices and integrated into hospital EHR systems and clinical workflows. MyoVista Insights is described as a SaaS-based platform that can generate per‑test revenues and host algorithms from multiple partners through an AI‑ECG marketplace.
HeartSciences’ disclosures emphasize that millions of ECGs are performed every week and that the company’s objective is to make ECG a more valuable cardiac screening tool, especially in frontline or point‑of‑care settings. The company highlights that reimbursement codes have been approved for AI‑ECG algorithms, which, according to its statements, are additive to conventional ECG test reimbursement and may support AI‑ECG adoption across the healthcare system.
Regulatory and Exchange Information
HeartSciences Inc. is incorporated in Texas and its common stock trades on The Nasdaq Stock Market LLC under the symbol HSCS. Warrants associated with the company trade under the symbol HSCSW. The company has disclosed that it previously received a notice from Nasdaq regarding compliance with the minimum stockholders’ equity requirement for continued listing and that it subsequently regained compliance, with Nasdaq indicating that the matter was closed.
The company files reports with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and current reports on Form 8‑K. These filings provide additional information on its financial condition, regulatory matters, and business developments.
Role in Healthcare and Cardiac Screening
HeartSciences positions itself as a company focused on transforming ECGs/EKGs to enable earlier detection of heart disease. Its disclosures describe a goal of modernizing legacy ECG systems through AI‑enabled software and hardware, with an emphasis on integration into existing clinical care pathways. By working with clinical experts, the company states that it aims to design solutions that are usable in routine clinical practice and that can support clinicians in making earlier and more informed cardiac assessments.
Stock Performance
HeartSciences (HSCS) closed at $2.08 on November 16, 2026. Over the past 12 months, the price has lost 32.2%.
HSCS Metrics & Rankings
Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
HeartSciences has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition, fda approval, crypto, earnings. View all HSCS news →
SEC Filings
HeartSciences has filed 10 recent SEC filings, including 3 Form 8-K, 1 Form 8-K/A, 1 Form SCHEDULE 13G, 1 Form SCHEDULE 13D/A. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all HSCS SEC filings →
Financial Highlights
HeartSciences generated $4K in revenue in FY2026, retaining a 59.1% gross margin, operating income reached -$8.4M, and net income was -$9.1M. The company generated -$7.4M in operating cash flow. The current ratio was 0.53, measuring current assets divided by current liabilities.
Upcoming Events
Special shareholder meeting
HeartSciences has 1 upcoming scheduled event. The next event, "Special shareholder meeting", is scheduled for November 19, 2026 (in 2 days). Investors can track these dates to stay informed about potential catalysts that may affect the HSCS stock price.
Short Interest History
Short interest in HeartSciences (HSCS) currently stands at 124.1 thousand shares, up 96.5% from the previous reporting period, representing 3.1% of the float. Since November 2025, short interest has increased by 238.2%.
Days to Cover History
Days to cover for HeartSciences (HSCS) currently stands at 1.4 days, up 37% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 37%. Across the settlements charted above, it has ranged from 1.0 to 4.0 days.
HSCS Company Profile & Sector Positioning
HeartSciences (HSCS) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing HSCS often look at related companies in the same sector, including SiNtx Technologies, Inc. (SINT), Iridex Corp (IRIX), Lifeward Ltd. (LFWD), PAVmed Inc. (PAVM), and Aethlon Medical Inc (AEMD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate HSCS's relative position within its industry.